video wires

These three ASX stocks may be seeing end-of-financial-year selling. Here’s why that could present an opportunity.

Trilogy Funds is looking to invest in a convenience retail asset - here's your opportunity to join them.

Ox Capital's investment approach focuses on identifying long-term winners with quality franchises and a strong valuation discipline.

James Gerrish and Henry Jennings wrap up the year that was, look ahead to FY26, and share two cracking stock picks for the coming 12 months.

Epsilon Direct Lending’s Joe Millward explains why the booming mid-market space is fertile ground for quality private lending opportunities.

Market Matters' James Gerrish and Marcus Today's Henry Jennings run the ruler over the best & worst-performing stocks of the past 12 months.

Portfolio manager Kera Van Valen says she targets companies with growing free cashflow to return to investors as dividends.

Alphinity's Stuart Welch highlights the importance of earnings momentum and shares how his team hunts for companies displaying it.

Market veteran Mark Mobius says the rules for investing in emerging markets have changed and so has his approach.

Epsilon's Joe Millward explains the facts behind banks’ corporate lending and the opportunities companies like Epsilon are seizing.

The $40 billion ASX bank hybrid market is going to disappear by 2032 and investors want an alternative that offers similar yields, liquidity, and credit default risks....

Join Datt Capital’s Emanuel Datt and Yarra Capital’s Michael Steele as they analyse five ASX small caps disrupting their industries.

One of Wall Street's top investors talks on building great culture at a financial services business and being a leader.

With the Schroder Specialist Private Equity Fund turning five, Claire Smith spoke with us about the journey and key wins so far.

Join Datt Capital’s Emanuel Datt and Yarra Capital’s Michael Steele on the hunt for ASX names that could become tomorrow's leaders.

Vinva's systematic approach to investing in global equities is now available to wholesale and retail investors.

Deep expertise, high conviction investing, in some of the most exciting and innovative healthcare companies in the world.

Join Datt Capital’s Emanuel Datt and Yarra Capital’s Michael Steele on the hunt for ASX small caps with huge upside potential.

Specialist expertise, months of due dilligence, and high conviction investments - KP Rx's formula for healthcare growth investing.

Ex-20, not ex-growth: How First Sentier Investors finds Australia’s quiet compounders and holds them for the long run.